1,193 results on '"Hull, Mark"'
Search Results
2. Building Bridges: Describing a Process for Indigenous Engagement in Epidemiology
3. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
4. Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n–3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial
5. Navigating patterns of oral PrEP use: A qualitative longitudinal study of gay, bisexual, and queer men's dynamic practices of pausing, on-demand, and stopping PrEP in Canada
6. Impact of screening and doxycycline prevention on the syphilis epidemic among men who have sex with men in British Columbia: a mathematical modelling study
7. “To do so in a patient-centred way is not particularly lucrative”: The effects of neoliberal health care on PrEP implementation and delivery
8. Can we achieve better trial recruitment by presenting patient information through multimedia? Meta-analysis of ‘studies within a trial’ (SWATs)
9. Preventative behaviours and COVID-19 infection in a Canadian cohort of people living with HIV
10. Disjuncture between self-perceived and clinically assessed risk of HIV among gay, bisexual, and other men who have sex with men in Ontario and British Columbia, Canada
11. APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial
12. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
13. Reinfection incidence and risk among people treated for recent hepatitis C virus infection
14. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada
15. Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328)
16. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination
17. The Fox is Strong for its Size
18. On the Theory of Space-Time and Relativity
19. The Big Bass Liftoff Scenario
20. Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis
21. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy
22. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study
23. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.
24. Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)
25. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
26. PrEP-related stigma and PrEP use among gay, bisexual and other men who have sex with men in Ontario and British Columbia, Canada
27. Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learning
28. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
29. Fish oil supplement use modifies the relationship between dietary oily fish intake and plasma n-3 PUFA levels: an analysis of the UK Biobank
30. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
31. The syndemic effect of HIV/HCV co-infection and mental health disorders on acute care hospitalization rate among people living with HIV/AIDS : a population-based retrospective cohort study
32. Fatty acid desaturaseinsertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n–3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial
33. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
34. Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
35. Community-Based Participatory Approaches to Knowledge Translation: HIV Prevention Case Study of the Investigaytors Program
36. Routine HIV testing in acute care hospitals: Changing practice to curb a local HIV epidemic in Vancouver, BC
37. Supplementary Figure 3 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
38. Supplementary Figure 2 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
39. Supplementary Figure 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
40. Table 3 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
41. Table 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
42. Supplementary Table 2 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
43. Data from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
44. Supplementary Table 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
45. Table 2 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
46. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol
47. Figure 1 from Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
48. FADS2Indel polymorphism rs66698963 predicts colorectal polyp prevention by then-3 fatty acid EPA
49. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial
50. A risk-stratified approach to colorectal cancer prevention and diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.